393 related articles for article (PubMed ID: 16296784)
1. Antibody-cytotoxic agent conjugates for cancer therapy.
Chen J; Jaracz S; Zhao X; Chen S; Ojima I
Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
3. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
4. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
5. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in tumor-targeting anticancer drug conjugates.
Jaracz S; Chen J; Kuznetsova LV; Ojima I
Bioorg Med Chem; 2005 Sep; 13(17):5043-54. PubMed ID: 15955702
[TBL] [Abstract][Full Text] [Related]
7. Drug-conjugated monoclonal antibodies for the treatment of cancer.
Lambert JM
Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
[TBL] [Abstract][Full Text] [Related]
8. Antibody conjugate therapeutics: challenges and potential.
Teicher BA; Chari RV
Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
[TBL] [Abstract][Full Text] [Related]
10. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
Shapira S; Lisiansky V; Arber N; Kraus S
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
[TBL] [Abstract][Full Text] [Related]
11. [Targeting of antitumor drugs with monoclonal antibodies].
Monneret C; Florent JC
Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
[TBL] [Abstract][Full Text] [Related]
12. [Immunoconjugates, drug-armed antibodies to fight against cancer].
Haeuw JF; Caussanel V; Beck A
Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
14. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
Pimm MV
Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
[TBL] [Abstract][Full Text] [Related]
15. Antibody conjugates and therapeutic strategies.
McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
[TBL] [Abstract][Full Text] [Related]
16. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy.
Russell SM; Krauer KG; McKenzie IF; Pietersz GA
Cancer Res; 1990 Sep; 50(18):6028-33. PubMed ID: 2393867
[TBL] [Abstract][Full Text] [Related]
17. Antibody-targeted drugs for the therapy of cancer.
Pietersz GA; Krauer K
J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
[TBL] [Abstract][Full Text] [Related]
18. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
19. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
[TBL] [Abstract][Full Text] [Related]
20. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
Cancer Lett; ; . PubMed ID: 17698286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]